Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Q3 2025 value amounting to -$603000.0.

  • Ironwood Pharmaceuticals' Other Working Capital Changes fell 6890.76% to -$603000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 5588.99%. This contributed to the annual value of -$2.2 million for FY2024, which is 4843.6% up from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Other Working Capital Changes stood at -$603000.0, which was down 6890.76% from -$584000.0 recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Other Working Capital Changes ranged from a high of $3.7 million in Q1 2023 and a low of -$6.1 million during Q4 2023
  • In the last 5 years, Ironwood Pharmaceuticals' Other Working Capital Changes had a median value of -$483000.0 in 2022 and averaged -$695473.7.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 85962.73% in 2023, then crashed by 72253.52% in 2025.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Other Working Capital Changes stood at -$476000.0 in 2021, then tumbled by 245.8% to -$1.6 million in 2022, then crashed by 270.66% to -$6.1 million in 2023, then increased by 28.62% to -$4.4 million in 2024, then surged by 86.15% to -$603000.0 in 2025.
  • Its last three reported values are -$603000.0 in Q3 2025, -$584000.0 for Q2 2025, and -$572000.0 during Q1 2025.